Primary care and abortion provider perspectives on mail-order medication abortion: a qualitative study

Author:

Raifman Sarah,Gurazada Tanvi,Beaman Jessica,Biggs M. Antonia,Schwarz Eleanor Bimla,Gold Marji,Grossman Daniel

Abstract

Abstract Background This qualitative study aims to assess perspectives of clinicians and clinic staff on mail-order pharmacy dispensing for medication abortion. Methods Participants included clinicians and staff involved in implementing a mail-order dispensing model for medication abortion at eleven clinics in seven states as part of a prospective cohort study, which began in January 2020 (before the FDA removed the in-person dispensing requirement for mifepristone). From June 2021 to July 2022, we invited participants at the participating clinics, including six primary care and five abortion clinics, to complete a semi-structured video interview about their experiences. We then conducted qualitative thematic analysis of interview data, summarizing themes related to perceived benefits and concerns about the mail-order model, perceived patient interest, and potential barriers to larger-scale implementation. Results We conducted 24 interviews in total with clinicians (13 physicians and one nurse practitioner) and clinic staff (n = 10). Participants highlighted perceived benefits of the mail-order model, including its potential to expand abortion services into primary care, increase patient autonomy and privacy, and to normalize abortion services. They also highlighted key logistical, clinical, and feasibility concerns about the mail-order model, and specific challenges related to integrating abortion into primary care. Conclusion Clinicians and clinic staff working in primary care and abortion clinics were optimistic that mail-order dispensing of medication abortion can improve the ability of some providers to provide abortion and enable more patients to access services. The feasibility of mail-order pharmacy dispensing of medication abortion following the Supreme Court Dobbs decision is to be determined. Trial registration Registry: Clinicaltrials.gov. Trial registration number: NCT03913104. Date of registration: first submitted on April 3, 2019 and first posted on April 12, 2019.

Funder

Society of Family Planning

Publisher

Springer Science and Business Media LLC

Reference32 articles.

1. Medication Abortion Now Accounts for More Than Half of All US Abortions. Guttmacher Institute 2022. https://www.guttmacher.org/article/2022/02/medication-abortion-now-accounts-more-half-all-us-abortions (accessed June 27, 2023).

2. Cavazzoni P. CDER. Response letter from FDA CDER to American Association of Pro-life obstetricians. and Gynecologists and American College of Pediatricians; 2021.

3. American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins—Gynecology. Society of Family Planning. Medication abortion up to 70 days of Gestation: ACOG Practice Bulletin, Number 225. Obstet Gynecol. 2020;136:e31–47.

4. NAF. Clinical Policy guidelines for Abortion Care. National Abortion Federation; 2024.

5. Upadhyay UD, Koenig LR, Meckstroth K, Ko J, Valladares ES, Biggs MA. Effectiveness and safety of telehealth medication abortion in the USA. Nat Med 2024:1–8. https://doi.org/10.1038/s41591-024-02834-w.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3